Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Guangzhou Baiyunshan Pharmaceutical Holdings Company ( (HK:0874) ) has provided an announcement.
Guangzhou Baiyunshan Pharmaceutical Holdings Company announced that its subsidiary, Guangzhou Pharmaceuticals Co., Ltd (GP Corp.), will commence public trading on the National Equities Exchange and Quotations (NEEQ) starting 20 May 2025. This move, approved by the Hong Kong Stock Exchange, positions GP Corp. in the innovation tier of NEEQ, potentially enhancing its market visibility and investor engagement.
The most recent analyst rating on (HK:0874) stock is a Hold with a HK$25.40 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
More about Guangzhou Baiyunshan Pharmaceutical Holdings Company
Guangzhou Baiyunshan Pharmaceutical Holdings Company is a joint stock company based in the People’s Republic of China, operating in the pharmaceutical industry. It focuses on the development and distribution of pharmaceutical products and services.
YTD Price Performance: -5.60%
Average Trading Volume: 1,444,254
Technical Sentiment Signal: Sell
Current Market Cap: HK$44.63B
For an in-depth examination of 0874 stock, go to TipRanks’ Stock Analysis page.